Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.52 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.52 |
| ▸ | AURKA | O14965 | 4/20 | 0.49 |
| ▸ | ABL1 | P00519 | 3/20 | 0.48 |
| ▸ | BCR | P11274 | 3/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | SYK | P43405 | 1/20 | 0.43 |
| ▸ | DDR2 | Q16832 | 2/20 | 0.43 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.43 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | APEX1 | P27695 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.42 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL676557 | 0.86 | AURKA (0.68) | AURKASYK | |
| SCHEMBL4239038 | 0.81 | AURKA (0.70) | EGFRERBB4AURKAABL1BCR | |
| SCHEMBL1387447 | 0.73 | THRB (0.80) | EGFRERBB4AURKAABL1BCR | |
| SCHEMBL4235267 | 0.70 | AURKA (0.55) | EGFRERBB4AURKAABL1BCR | |
| SCHEMBL4239378 | 0.69 | ABL1 (0.69) | AURKAABL1BCRKDM4EMAPT | |
| SCHEMBL242230 | 0.69 | EGFR (1.00) | EGFRERBB4AURKATHRBKDM4E | |
| SCHEMBL4239042 | 0.68 | THRB (0.68) | EGFRERBB4AURKATHRBKDM4E | |
| SCHEMBL4237718 | 0.68 | THRB (0.55) | EGFRERBB4AURKAABL1BCR | |
| SCHEMBL4234986 | 0.68 | AURKA (0.55) | EGFRERBB4AURKAABL1BCR | |
| SCHEMBL12431488 | 0.68 | EGFR (0.69) | EGFRERBB4ABL1BCRTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120076781-A1 | METHODS OF TREATING CANCERS WITH HER3 ANTISENSE OLIGONUCLEOTIDES | SANTARIS PHARMA A/S (DK) | 2012-03-29 | — | — | US | claimed |
| EP-2419110-A1 | METHODS OF TREATING CANCERS WITH HER3 ANTISENSE OLIGONUCLEOTIDES | Enzon Pharmaceuticals, Inc. (US) | 2012-02-22 | — | — | EP | claimed |
| US-20120004285-A1 | ERBB-3 (HER3)-SELECTIVE COMBINATION THERAPY | ENZON PHARMACEUTICALS, INC. (US) | 2012-01-05 | — | — | US | claimed |
| EP-2376087-A1 | ERBB-3 (HER3)-SELECTIVE COMBINATION THERAPY | Santaris Pharma A/S (DK) | 2011-10-19 | — | — | EP | claimed |
| WO-2010120861-A1 | METHODS OF TREATING CANCERS WITH HER3 ANTISENSE OLIGONUCLEOTIDES | ENZON PHARMACEUTICALS, INC. (US) | 2010-10-21 | — | — | WO | claimed |
| WO-2010054051-A1 | ERBB-3 (HER3)-SELECTIVE COMBINATION THERAPY | SANTARIS PHARMA A/S (DK) | 2010-05-14 | — | — | WO | claimed |
| US-20250197949-A1 | SYSTEMS AND METHODS FOR PREDICTING PROSTATE CANCER RECURRENCE | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2025-06-19 | — | — | US | disclosed |
| CN-118159647-A | Method for producing cardiomyocyte layer, and use thereof | 富士胶片株式会社 | 2024-06-07 | — | — | CN | disclosed |
| WO-2023074783-A1 | METHOD FOR PRODUCING MYOCARDIAL CELL LAYER, MYOCARDIAL CELL LAYER, AND USE THEREOF | 富士フイルム株式会社 | 2023-05-04 | — | — | WO | disclosed |
| US-9815893-B2 | Anti-VEGF antibodies and their uses | ABBVIE BIOTHERAPEUTICS INC. (US) | 2017-11-14 | — | — | US | disclosed |
| EP-2894167-B1 | Anti-VEGF Antibodies and their uses | ABBVIE BIOTHERAPEUTICS INC (US) | 2017-11-08 | — | — | EP | disclosed |
| EP-2925778-B1 | ANTI-VEGF ANTIBODIES AND THEIR USES | ABBVIE BIOTHERAPEUTICS INC (US) | 2017-11-01 | — | — | EP | disclosed |
| EP-2493929-B1 | ANTI-EGFR ANTIBODIES AND THEIR USES | ABBVIE BIOTHERAPEUTICS INC (US) | 2017-08-16 | — | — | EP | disclosed |
| WO-2011084496-A1 | ANTI-HER2 ANTIBODIES AND THEIR USES | ABBOTT BIOTHERAPEUTICS CORP. (US) | 2011-07-14 | — | — | WO | disclosed |
| US-20110117110-A1 | ANTI-EGFR ANTIBODIES AND THEIR USES | FACET BIOTECH CORPORATION (US) | 2011-05-19 | — | — | US | disclosed |
| WO-2011059762-A1 | ANTI-EGFR ANTIBODIES AND THEIR USES | ABBOTT BIOTHERAPEUTICS CORP. (US) | 2011-05-19 | — | — | WO | disclosed |
| US-20100322931-A1 | ANTI-VEGF ANTIBODIES AND THEIR USES | ABBVIE BIOTHERAPEUTICS INC. | 2010-12-23 | — | — | US | disclosed |
| WO-2010148223-A2 | ANTI-VEGF ANTIBODIES AND THEIR USES | FACET BIOTECH CORPORATION (US) | 2010-12-23 | — | — | WO | disclosed |
| WO-2010120861-A1 | METHODS OF TREATING CANCERS WITH HER3 ANTISENSE OLIGONUCLEOTIDES | ENZON PHARMACEUTICALS, INC. (US) | 2010-10-21 | — | — | WO | disclosed |
| WO-2008157753-A1 | METHODS OF TREATMENT FOR SPINAL MUSCULAR ATROPHY | SMA FOUNDATION (US) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120076781-A1 | METHODS OF TREATING CANCERS WITH HER3 ANTISENSE OLIGONUCLEOTIDES | ERBB3, ERBB2, EGFR | EGFR 3/4885ERBB4 4/4885AURKA 275/4885 |
| US-20120004285-A1 | ERBB-3 (HER3)-SELECTIVE COMBINATION THERAPY | ERBB3, ERBB2, EGFR | EGFR 3/4885ERBB4 4/4885AURKA 611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.